Skip to main content
. 2021 Aug 5;5(15):3016–3020. doi: 10.1182/bloodadvances.2021004176

Figure 1.

Figure 1.

Treatment course of patients receiving serial BCMA-targeted therapies. CAR T-cell expression and serum free light chain (SFLC) expression (A) and sBCMA and anti-CAR antibodies (B) in patient #1 receiving 2 infusions of BCMA-targeted CAR T cells and belantamab. CAR T-cell expression and circulating plasma cells (C) and sBCMA and anti-CAR antibodies (D) in patient #2 receiving 1 infusion of BCMA-targeted CAR T cells followed by belantamab.